All In Biotech

Drug Trial Radar · NCT05280509

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Last checked: Nov 19, 2026Latest source record: Feb 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Jun 9, 2022

Primary completion

Oct 2025

Study completion Apr 2027

Sponsor

Lead sponsor
Telios Pharma, Inc.Industry
Sponsor type
Industry
First posted
Mar 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.

Conditions

  • Myelofibrosis
  • Primary Myelofibrosis
  • Post-PV MF
  • Post-ET Myelofibrosis

Interventions

  • TL-895Drug

    TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

  • RuxolitinibDrug

    Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b - Recommended Phase 2 dose of TL-895 in combination with ruxolitinibTime frame: 28 days
  2. Phase 2 - Spleen Volume Reduction (SVR) at Week 24Time frame: 24 Weeks

Locations

19 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Gabrail Cancer Center

    Canton, Ohio · Recruiting

  • University of Cincinnati (UC)

    Cincinnati, Ohio · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • CHU Angers

    Angers, France · Recruiting

  • AP-HM - Hôpital de la Timone

    Marseille, France · Recruiting

  • CHU de Nice - Hopital L'Archet II

    Nice, France · Recruiting

  • Hôpital Saint Louis - AP-HP

    Paris, France · Recruiting

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France · Recruiting

  • Marien Hospital Duesseldorf

    Düsseldorf, Germany · Recruiting

  • Klinik fur Innere Medizin IV - Hamatologie/Onkologie, Universitatsklinikum Hall

    Halle, Germany · Recruiting

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola

    Bologna, Italy · Recruiting

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

    Milan, Italy · Recruiting

  • Azienda Ospedaliera di Perugia-Ospedale S. Maria della Misericordia

    Perugia, Italy · Recruiting

  • Pratia Onkologia Katowice

    Katowice, Poland · Recruiting

  • Hospital Universitari Arnau de Vilanova

    Lleida, Spain · Recruiting

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain · Recruiting

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain · Recruiting

  • Hospital Quironsalud de Zaragoza

    Zaragoza, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.